Peritoneal dissemination complicating morcellation of uterine mesenchymal neoplasms

• Published in: PloS one 2012-11, Vol.7 (11), p.e50058-e50058
• Main Authors: Seidman, Michael A, Oduyebo, Titilope, Muto, Michael G, Crum, Christopher P, Nucci, Marisa R, Quade, Bradley J
• Format: Article
• Language: English
• Subjects: Adult; Biological products; Biology; Consultation; Endometrial cancer; Endometrium; Female; Fibroids; Health aspects; Humans; Hysterectomy; Laparoscopy; Leiomyoma - pathology; Leiomyoma - surgery; Leiomyosarcoma - pathology; Leiomyosarcoma - surgery; Malignancy; Medical diagnosis; Medical records; Medicine; Mesenchyme; Mortality; Muscles; Muscular system; Neoplasm Seeding; Neoplasms; Peritoneum; Peritoneum - pathology; Sarcoma; Smooth muscle; Stem cells; Tumors; Uterine cancer; Uterine Neoplasms - diagnosis; Uterine Neoplasms - pathology; Uterine Neoplasms - surgery; Uterus
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0050058

Power morcellation has become a common technique for the minimally invasive resection of uterine leiomyomas. This technique is associated with dissemination of cellular material throughout the peritoneum. When morcellated uterine tumors are unexpectedly found to be leiomyosarcomas or tumors with atypical features (atypical leiomyoma, smooth muscle tumor of uncertain malignant potential), there may be significant clinical consequences. This study was undertaken to determine the frequency and clinical consequence of intraperitoneal dissemination of these neoplasms. From 2005-2010, 1091 instances of uterine morcellation were identified at BWH. Unexpected diagnoses of leiomyoma variants or atypical and malignant smooth muscle tumors occurred in 1.2% of cases using power morcellation for uterine masses clinically presumed to be "fibroids" over this period, including one endometrial stromal sarcoma (ESS), one cellular leiomyoma (CL), six atypical leiomyomas (AL), three smooth muscle tumor of uncertain malignant potential (STUMPs), and one leiomyosarcoma (LMS). The rate of unexpected sarcoma after the laparoscopic morcellation procedure was 0.09%, 9-fold higher than the rate currently quoted to patients during pre-procedure briefing, and this rate may increase over time as diagnostically challenging or under-sampled tumors manifest their biological potential. Furthermore, when examining follow-up laparoscopies, both from in-house and consultation cases, disseminated disease occurred in 64.3% of all tumors (zero of one ESS, one of one CL, zero of one AL, four of four STUMPs, and four of seven LMS). Only disseminated leiomyosarcoma, however, was associated with mortality. Procedures are proposed for pathologic evaluation of morcellation specimens and associated follow-up specimens. While additional study is warranted, these data suggest uterine morcellation carries a risk of disseminating unexpected malignancy with apparent associated increase in mortality much higher than appreciated currently.